Altuviiio (Antihemophilic Factor [Recombinant], Fc-VWF-XTEN Fusion Protein-Ehtl) for Haemophilia

Overview
Altuviiio is approved by the U.S. Food and Drug Administration (FDA) for use in adults and children with hemophilia A (congenital factor VIII deficiency). It is indicated for routine prophylaxis to reduce bleeding episodes, on-demand treatment and control of bleeding episodes, and for perioperative management (managing bleeding during surgery). Altuviiio is also known by its drug name, antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl.

Altuviiio is a recombinant clotting factor, specifically factor VIII (8), produced using DNA technology. It works by replacing the missing or defective factor VIII in people with hemophilia A, helping their blood to clot more effectively and thereby reducing or preventing bleeding episodes.

How do I take it?
Prescribing information states that Altuviiio is given as an intravenous (IV) infusion. For routine prophylaxis, it is typically administered once weekly. For on-demand treatment of bleeding or for surgical procedures, it is also given as an IV infusion, usually once per episode. The medication should always be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Altuviiio include headache and arthralgia (joint pain).

Rare but serious side effects may include severe hypersensitivity reactions such as anaphylaxis (a life-threatening allergic reaction) and the development of neutralizing antibodies (inhibitors) to factor VIII, which can reduce the drug’s effectiveness. If a person experiences symptoms of an allergic reaction or their bleeding is not controlled with appropriate dosing, they should seek immediate medical attention.

For more information about this treatment, visit:
Label: Altuviiio (Antihemophilic Factor- Recombinant, Fc-Vwf-Xten Fusion Protein-Ehtl Kit — DailyMed